Pharma BD Deal Intelligence
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Victoza captured 26% of GLP-1 class prescriptions and 33.9% of new starts within months of launch — foreshadowing the share-erosion challenge AZ/BMS would…
AstraZeneca paid BMS ~$3.4B cash for 50/50 profit share on Amylin's diabetes portfolio (Byetta, Bydureon, metreleptin); optional $135M for equal governance…
Subsequent head-to-head data and Lilly's dulaglutide entry confirmed the post-deal concern that Bydureon's once-weekly advantage was eroding faster than the…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Following BMS acquisition of Amylin, AstraZeneca paid BMS $3.4B cash to enter 50/50 profit share on the Amylin GLP-1 portfolio (Byetta, Bydureon). Optional $135M for equal governance rights. Expanded the existing BMS-AZ diabetes alliance.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Bristol-Myers Squibb Company / Amylin diabetes alliance (this deal) | 2012 | $3.5B | 77 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2012 deals · AstraZeneca PLC deals · Metabolic deals